Predictive diagnosis of the risk of breast cancer recurrence after surgery by single-particle quantum dot imaging

[1]  Wolfgang J. Parak,et al.  Back to Basics: Exploiting the Innate Physico‐chemical Characteristics of Nanomaterials for Biomedical Applications , 2014 .

[2]  Lay Poh Tan,et al.  Nanoparticles strengthen intracellular tension and retard cellular migration. , 2014, Nano letters.

[3]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[4]  J. Baselga,et al.  Trastuzumab emtansine for HER2-positive advanced breast cancer. , 2012, The New England journal of medicine.

[5]  Noriaki Ohuchi,et al.  Development of a quantitative diagnostic method of estrogen receptor expression levels by immunohistochemistry using organic fluorescent material-assembled nanoparticles. , 2012, Biochemical and biophysical research communications.

[6]  T. Yambe,et al.  In vivo imaging of the molecular distribution of the VEGF receptor during angiogenesis in a mouse model of ischemia. , 2011, Blood.

[7]  Massimo Cristofanilli,et al.  Molecular mechanisms of metastasis in breast cancer—clinical applications , 2010, Nature Reviews Clinical Oncology.

[8]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[9]  Noriaki Ohuchi,et al.  Nano-imaging of the lymph network structure with quantum dots , 2010, Nanotechnology.

[10]  Noriaki Ohuchi,et al.  In Vivo Nano-imaging of Membrane Dynamics in Metastatic Tumor Cells Using Quantum Dots* , 2009, The Journal of Biological Chemistry.

[11]  N. McCarthy.  Metastasis: Influencing bad behaviour , 2009, Nature Reviews Cancer.

[12]  Gang-yu Liu,et al.  A nanoengineering approach for investigation and regulation of protein immobilization. , 2008, ACS nano.

[13]  Hideo Higuchi,et al.  Stepwise movements in vesicle transport of HER2 by motor proteins in living cells. , 2007, Biophysical journal.

[14]  J. Trejo,et al.  Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer , 2007, Journal of Cell Science.

[15]  Noriaki Ohuchi,et al.  In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. , 2007, Cancer research.

[16]  Tomonobu M. Watanabe,et al.  Reduction in nonfluorescence state of quantum dots on an immunofluorescence staining. , 2006, Biochemical and biophysical research communications.

[17]  P. Schedin.  Pregnancy-associated breast cancer and metastasis , 2006, Nature Reviews Cancer.

[18]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[19]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[20]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[21]  S. Nie,et al.  In vivo cancer targeting and imaging with semiconductor quantum dots , 2004, Nature Biotechnology.

[22]  C. Der,et al.  Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion , 2004, Molecular and Cellular Biology.

[23]  J. Post,et al.  Quantum dot ligands provide new insights into erbB/HER receptor–mediated signal transduction , 2004, Nature Biotechnology.

[24]  J. Baleja,et al.  Structural basis for thrombin activation of a protease-activated receptor: inhibition of intramolecular liganding. , 2003, Chemistry & biology.

[25]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  David L Rimm,et al.  Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome. , 2003, Cancer research.

[27]  He-long Zhang,et al.  A third‐generation matrix metalloproteinase (MMP) inhibitor (ONO‐4817) combined with docetaxel suppresses progression of lung micrometastasis of MMP‐expressing tumor cells in nude mice , 2003, International journal of cancer.

[28]  D. Rimm,et al.  Automated subcellular localization and quantification of protein expression in tissue microarrays , 2002, Nature Medicine.

[29]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Fingleton,et al.  Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Kurosumi,et al.  Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6 , 1999, British Journal of Cancer.

[32]  Reuven Reich,et al.  Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.

[33]  P. Ravdin,et al.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.

[34]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[35]  M. Bruchez,et al.  Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots , 2003, Nature Biotechnology.

[36]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.